IceCure Medical's New $4 Million Offering Signals Growth for Cryoablation Technology IceCure Medical Ltd. announces a $4 million registered direct offering alongside a concurrent private placement, enhancing its cryoablation technology market.

IceCure Medical's New $4 Million Offering Signals Growth for Cryoablation Technology #Israel #Caesarea #IceCure_Medical #Cryoablation #Nasdaq_ICCM

IceCure's Promising 5-Year Study Results for Kidney Cancer Cryoablation Show High Recurrence-Free Rates IceCure Medical has revealed impressive five-year results from its ICESECRET study, highlighting significant recurrence-free rates for kidney cancer treatment, promoting its minimally invasive ProSense® technology.

IceCure's Promising 5-Year Study Results for Kidney Cancer Cryoablation Show High Recurrence-Free Rates #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical's ProSense® Cryoablation Gains FDA Approval for Breast Cancer Study The FDA has approved IceCure Medical's ProSense® cryoablation system for a post-marketing study in low-risk breast cancer treatment, engaging major U.S. medical institutions.

IceCure Medical's ProSense® Cryoablation Gains FDA Approval for Breast Cancer Study #United_States #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical's ProSense Cryoablation: A Game-Changer for Breast Fibroadenoma Treatment IceCure Medical's recent study reveals the effectiveness of ProSense® cryoablation for treating breast fibroadenomas, fostering potential shifts in clinical guidelines.

IceCure Medical's ProSense Cryoablation: A Game-Changer for Breast Fibroadenoma Treatment #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

Robot-assisted CT-guided cryoablation of pulmonary metastases: an IDEAL stage 2a prospective development study - European Radiology Objectives To evaluate the feasibility, safety, and technical performance of robot-assisted CT-guided cryoablation for pulmonary metastases. Materials and methods A single-centre IDEAL stage 2a…

"Robot-assisted navigation represents a meaningful advancement in #cryoablation, as it facilitates precise probe placement while minimizing the need for repeated manipulations, even when complex trajectories are required." - Sonja Jankovic

buff.ly/EqJEXMa (Nicos Fotiadis et al.)

IceCure Medical Announces CFO Departure After Key Achievements in Nine Years IceCure Medical has announced the departure of CFO Ronen Tsimerman after nearly a decade, highlighting significant milestones achieved during his tenure.

IceCure Medical Announces CFO Departure After Key Achievements in Nine Years #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Applauds ASBrS for Including Cryoablation in Breast Cancer Guidelines IceCure celebrates the American Society of Breast Surgeons' new guidelines, endorsing cryoablation for low-risk breast cancer patients. This marks a significant advancement in breast cancer treatment options.

IceCure Applauds ASBrS for Including Cryoablation in Breast Cancer Guidelines #Israel #Caesarea #Cryoablation #IceCure #ASBrS

This BOOSTER phase II trial shows that adding local ablation to anti‑PD‑1/PD‑L1 #immunotherapy in advanced #NSCLC with oligo‑residual disease prolongs #PFS, trends toward improved OS, and #cryoablation may offer greater benefit with good safety.

#STTT: doi.org/10.1038/s413...

IceCure Medical Anticipates Record Sales in North America Following FDA Clearance of ProSense® Cryoablation System IceCure Medical is set to report record fourth quarter sales in North America, thanks to FDA's approval of the ProSense® system for low-risk breast cancer treatment.

IceCure Medical Anticipates Record Sales in North America Following FDA Clearance of ProSense® Cryoablation System #USA #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure's ProSense® Cryoablation Gains Traction at RSNA 2025 Annual Meeting with Promising New Studies IceCure Medical's ProSense® Cryoablation was showcased in four independent breast cancer studies at the RSNA 2025 Annual Meeting, emphasizing its effectiveness and growing acceptance in non-surgical treatments.

IceCure's ProSense® Cryoablation Gains Traction at RSNA 2025 Annual Meeting with Promising New Studies #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical Advances Cryoablation Technology with New Patent in China for Improved Patient Outcomes IceCure Medical has received a Notice of Patent Allowance in China, enhancing their cryoablation systems. This advances patient care significantly.

IceCure Medical Advances Cryoablation Technology with New Patent in China for Improved Patient Outcomes #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

Transbronchial #Cryoablation for Early-Stage Non-Small Cell #LungCancer of the Central Airway Complicated by Idiopathic #PulmonaryFibrosis
onlinelibrary.wiley.com/doi/10.1002/...

Cost Comparison of Pulsed Field Ablation and Conventional Thermal Ablation for Atrial Fibrillation: A Systematic Review Background Pulsed field ablation (PFA) is an emerging non-thermal catheter ablation (CA) modality for the treatment of atrial fibrillation (AF), PFA has shown a relatively similar success rate but o...

Pulsed Field Ablation (PFA) is a safer, faster treatment for the irregular heartbeat called Atrial Fibrillation (AF). It costs less and improves patient outcomes better than traditional #ThermalAblation. #Cost‐Effectiveness #cryoablation onlinelibrary.wiley.com/doi/10.1111/...

This study shows that adding local #ablation to continuous #immunotherapy significantly prolongs PFS and OS in advanced #NSCLC patients with oligo-residual disease after anti-PD-1/L1 therapy, with #cryoablation offering added benefit.

#OpenAccess in #STTT: doi.org/10.1038/s413...

IceCure's Innovative Cryoablation System Enhances Lung Cancer Survival Rates Significantly IceCure's Cryoablation System, in combination with SBRT, leads to a remarkable 92% disease-specific survival rate for lung cancer patients, significantly improving outcomes.

IceCure's Innovative Cryoablation System Enhances Lung Cancer Survival Rates Significantly #Israel #Caesarea #IceCure_Medical #Cryoablation #SBRT

Boston Scientific study finds cryoablation more cost-effective than surgery A Danish study finds cryoablation equally effective as robotic surgery for kidney cancer, but at 32% lower cost in patients with kidney cancer.

A new Danish study shows cryoablation is just as effective as robotic surgery for kidney cancer — but 32% cheaper and with shorter hospital stays. 🌍💙❄️

#News #KidneyCancer #Cryoablation #HealthcareInnovation #MedicalResearch #CancerTreatment #BostonScientific

Boston Scientific study finds cryoablation more cost-effective than surgery A Danish study finds cryoablation equally effective as robotic surgery for kidney cancer, but at 32% lower cost in patients with kidney cancer.

A new Danish study shows cryoablation is just as effective as robotic surgery for kidney cancer — but 32% cheaper and with shorter hospital stays. 🌍💙❄️

#News #KidneyCancer #Cryoablation #HealthcareInnovation #MedicalResearch #CancerTreatment #BostonScientific

Join us for today's webinar on cryoablation!
📌 October 16, 2025, 17:00-18:20 CEST
📄​ Programme: t.ly/8dBiY
✔️ Access the webinar: t.ly/YdfZn

#InterventionalRadiology #IRad #CIRSEwebinar #cryoablation

IceCure's Innovative ProSense® Cryoablation System Promotes Advanced Breast Cancer Care Discover how IceCure Medical's ProSense® system showcased innovative cryoablation technology at the TME Fall Summit, aiming to reshape breast cancer treatment.

IceCure's Innovative ProSense® Cryoablation System Promotes Advanced Breast Cancer Care #United_States #New_Orleans #IceCure_Medical #Cryoablation #ProSense

IceCure Medical Announced Participation in 2025 Maxim Growth Summit in NYC IceCure Medical will showcase its innovative cryoablation technology at the 2025 Maxim Growth Summit, marking a significant milestone for breast cancer treatment.

IceCure Medical Announced Participation in 2025 Maxim Growth Summit in NYC #United_States #New_York #IceCure_Medical #Cryoablation #ProSense

IceCure's ProSense® Showcases Promising Advances in Breast Cancer Care at EUSOBI 2025 IceCure Medical's ProSense® technology highlighted the potential of cryoablation as a minimally invasive treatment for early-stage breast cancer at EUSOBI 2025.

IceCure's ProSense® Showcases Promising Advances in Breast Cancer Care at EUSOBI 2025 #United_Kingdom #Cryoablation #ProSense #Aberdeen #IceCure

IceCure Medical Showcases Promising Cryoablation Results at CIRSE 2025 Annual Meeting IceCure Medical's ProSense® technology received positive feedback at the CIRSE 2025 Annual Meeting, showcasing innovative cryoablation studies and hands-on training sessions.

IceCure Medical Showcases Promising Cryoablation Results at CIRSE 2025 Annual Meeting #Israel #Barcelona #Cryoablation #ProSense #IceCure

Save the date for the upcoming free webinar on cryoablation!

📌 October 16, 2025, 17:00-18:20 CEST
📄​ Programme: t.ly/8dBiY
✔️ Registration: t.ly/lfyKb

#CIRSEwebinar #IRad #cryoablation

IceCure's ProSense® Shows High Effectiveness in Alleviating Endometriosis Pain IceCure Medical Ltd. announces that its ProSense® cryoablation significantly reduces abdominal wall endometriosis pain, providing notable clinical benefits.

IceCure's ProSense® Shows High Effectiveness in Alleviating Endometriosis Pain #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense®

IceCure Medical Reports Promising Financial and Operational Progress in First Half of 2025 IceCure Medical announces its financial results for H1 2025, highlighting advancements in cryoablation technology and significant FDA interactions.

IceCure Medical Reports Promising Financial and Operational Progress in First Half of 2025 #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense®

IceCure Medical Urges Shareholders to Act Before Rights Offering Deadline IceCure Medical reminds shareholders of the rapidly approaching deadline for its rights offering. Don't miss your chance to invest in innovative cryoablation technology.

IceCure Medical Urges Shareholders to Act Before Rights Offering Deadline #Israel #Caesarea #IceCure_Medical #Cryoablation #Rights_Offering

IceCure Medical Launches Rights Offering for Growth and Innovation in Cryoablation Technology IceCure Medical has initiated a rights offering allowing existing shareholders to purchase shares and warrants, aiming to raise $10 million to further its innovative cryoablation technology.

IceCure Medical Launches Rights Offering for Growth and Innovation in Cryoablation Technology #Israel #Caesarea #IceCure_Medical #Cryoablation #Rights_Offering

IceCure Medical Reports Preliminary Financial Results for Q2 2025 Amid Delivery Delays IceCure Medical Ltd. announces preliminary financial results for Q2 2025, reporting $525,000 in product sales amidst temporary shipment delays.

IceCure Medical Reports Preliminary Financial Results for Q2 2025 Amid Delivery Delays #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

The chick chorioallantoic membrace model has been utilized for radiofrequency ablation and electroporation - the authors found it can also be a feasible platform for preclinical #cryoablation studies (Michael Scheschenja et al.)

#EuropeanRadiologyExperimental

buff.ly/8kYiJTv

IceCure Medical Sets Record Date for Major Rights Offering Up to $10 Million IceCure Medical Ltd. announces a landmark rights offering, enabling shareholders to invest in the future of cryoablation technology with a potential raise of up to $10 million.

IceCure Medical Sets Record Date for Major Rights Offering Up to $10 Million #Israel #Caesarea #IceCure_Medical #Cryoablation #Rights_Offering